← Back to Home

Reading Breast Cancer Signals from Nucleosomes in Blood: Experimental Test Explores Early Detection and Recurrence Risk

Combining epigenetic markers with computational analysis, researchers distinguished blood samples from patients and healthy women; whether the approach can be used for general-population screening still requires prospective validation.

By SURL BioNews

Whether breast cancer can be detected early and whether it may recur after treatment are two distinct but equally pressing questions in clinical care. A study published in *Nature* seeks shared clues in blood: nucleosomes released after cell death may retain epigenetic information from tumors, potentially helping identify cancer and offering clues to the disease’s future course.

A team from the Weizmann Institute of Science and the Hebrew University of Jerusalem focused on nucleosomes, structures formed by DNA wrapped around proteins. Chemical marks on these structures help regulate gene activity; even when the DNA sequence remains unchanged, differences in these marks may reflect the state of a cell. Using single-molecule microscopy with fluorescent labeling, the researchers measured the epigenetic features of large numbers of nucleosomes in blood, then used computational models to identify combinations associated with breast cancer.

According to information released by the research institutions, the initial blood analysis included 77 breast cancer patients followed for at least five years at the Mayo Clinic in the United States, along with 30 healthy women. The team reported that the model achieved 95% classification accuracy for early tumors confined to the breast and no larger than two centimeters. This reflects classification performance in specific patient and control samples and cannot be directly interpreted to mean that screening women in the general population would detect 95% of cancers.

With assistance from Sheba and Kaplan medical centers, the number of patient blood samples used in the study expanded to 188. The team said the test maintained good performance across different breast densities and breast cancer types. In situations where dense breasts may make imaging harder to interpret, blood signals offer another avenue for research; however, these results are not yet sufficient to establish the test’s place in existing screening pathways.

Clues to recurrence risk came from differences within tumors. The researchers found that some breast cancers not originally considered particularly aggressive also contained small numbers of highly aggressive cells with distinctive epigenetic features. When these features were more pronounced in blood, patients also had a higher risk of subsequent recurrence; combined with other markers, the model distinguished patients who experienced recurrence during follow-up from those who did not with 81% accuracy. This association still does not prove that these cells are the direct cause of recurrence.

Moving from the laboratory into clinical practice will depend on whether the test can handle complex situations that more closely reflect real-world care. Differences between patients with an established diagnosis and healthy controls may not fully represent a screening population whose diagnostic status is not yet known; overall accuracy alone also cannot account for missed cancers, false positives, or the probability that a positive result actually indicates cancer. Prospective screening validation is needed next, along with confirmation of whether recurrence risk classification can improve treatment decisions and patient outcomes, before the clinical value of these molecular clues can be determined.

References

  1. Medical Xpress / Hebrew University of Jerusalem
  2. Weizmann USA